A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Primary Objective
To evaluate the safety and tolerability of CB-011 therapy in patients with r/r MM to define the MTD/RDE to determine RP2D
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Daniel Sherbenou, MD, PhD
Study ID
Protocol Number: 23-0376
More information available at ClinicalTrials.gov: NCT05722418
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers